# Lead-212 PSV359 Therapy for Patients With Solid Tumors

Source: https://nuclide.cc/trials/nct06710756/  
Nuclide record `nct06710756` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of [203Pb]Pb-PSV359 in pancreatic ductal adenocarcinoma, gastric & gastro-oesophageal junction cancer, oesophageal cancer, colorectal cancer, ovarian cancer and head and neck squamous cell carcinoma, run by Perspective Therapeutics, now recruiting.

## Summary

Lead-212 PSV359 Therapy for Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT06710756 by Perspective Therapeutics, with 112 participants planned, started 2025-04-28 and due to reach its primary completion in 2028-01-31. Interventions recorded: [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06710756
- Phase: 1/2
- Setting: A Phase I/IIa Image-Guided, Alpha-Particle Therapy Study of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359 in Patients With Solid Tumors That Are Known to be Fibroblast Activation Protein (FAP)-Positive
- Sponsor: Perspective Therapeutics
- Enrolled: 112

## Sources

- ClinicalTrials.gov NCT06710756: https://clinicaltrials.gov/study/NCT06710756

## Connected records

- isotopes: [Lead-212](https://nuclide.cc/isotopes/pb-212/)
- companies: [Perspective Therapeutics](https://nuclide.cc/companies/perspective-therapeutics/)
- drugs: [Lead-212 PSV359](https://nuclide.cc/drugs/pb-212-psv359/)

---
JSON: https://nuclide.cc/api/v1/entities/nct06710756.json